| |
BUSCOPAN™ Reference Page
Description
Antispasmodic (spasmolytic) and anticholinergic drug which suppresses spasms of the digestive system.
Features
Only FDA-approved spasmolytic for control of abdominal pain associated with spasmodic colic, flatulent colic and simple impactions.
Antispasmodic (spasmolytic) to relax smooth muscles.
Does not disguise worsening of colic symptoms.
Clinical trial included horses as young as 4 months of age.
Benefits
Relaxes smooth muscles to suppress spasms of the digestive system and alleviate abdominal pain.
Successful treatment usually occurs within 5-30 minutes in most cases.
Does not reduce production of prostaglandins which might result in lowered mucus production and contribute to ulcers and diarrhea.
Clinical observations and diagnostics can continue while relief occurs.
Advantages
Relief is fast and effective. Buscopan was shown to have an 88% success rate in achieving a clinical response within 30 minutes of administration.1
1FOI Summary NADA 141-228 Administration of Buscopan results in heart rate elevation. Heart rate cannot be used as a valid indicator of severity of pain for 30 minutes after IV injection. Buscopan effects may be potentiated by use with other anticholinergic drugs. For I.V. use only. Safety for use in nursing foals, pregnant or lactating mares has not been established. See product labeling for complete use information.
Dosage & Administration
Administer a single injection of 0.3 mg/kg body weight (0.14 mg/lb), slowly IV. This is equivalent to 30 mg N-butylscopolammonium bromide per 100 kg (220 pounds) body weight or 1.5 mL of Buscopan Injectable Solution per 100 kg (220 pounds) body weight. See insert for complete Dosing Table.
Precautions
Store at controlled room temperature, 59-86º F (15-30º C). Not recommended for use in nursing foals or in pregnant or lactating mares, as safety has not been established. The effects may be potentiated by the concomitant use of other anticholinergic drugs. Studies of concomitant administration with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy. The safety has not been established for intramuscular (IM) administration. Administration results in heart rate elevation. Heart rate cannot be used as a valid indicator of severity of pain for 30 minutes following IV injection.
Uses
Buscopan is indicated for the control of abdominal pain (colic) associated with spasmodic colic, flatulent colic, and simple impactions in horses.
Warning
Not for use in humans. Not for horses intended for human consumption. Keep out of reach of children.
Product Information
| Name | Code | Size | | Buscopan? Injectable Solution | 370111 | 50 mL | | - | - | - | | - | - | - | | - | - | - | | - | - | - |
More Information
For more than 20 years, veterinarians in other countries have reached for BUSCOPAN to provide fast relief of many types of colic without masking clinical signs, allowing prognostic decisions to be made in as little as 30 minutes following treatment.
Contact Information
Boehringer Ingelhiem Vetmedica, Inc.
2621 North Belt Highway
St. Joseph, MO 64506
Information: 800-821-7467
Sales: 800-325-9167
Fax: 816-236-2717
email: mtittle@bi-vetmedica.com
internet: http://www.bi-vetmedica.com
General Product Information Documents
Technical Bulletins
Audio & Video
Marketing Documents
Product Photos and Product Art
| |
